实时荧光定量PCR法检测肺腺癌患者恶性胸腔积液中EML4-ALK融合基因突变的研究

Research of real-time fluorescent PCR to test the expression of EML4-ALK in pleural effusion fluid of patients with lung adenocarcinoma

目的探讨应用实时荧光定量PCR(FQ-PCR)方法检测原发性肺腺癌患者恶性胸腔积液中的EML4-ALK融合基因突变情况,并对指导克唑替尼治疗的可行性进行探讨。方法收集39例原发性肺腺癌患者的胸腔积液,使用FQ-PCR法检测EML4-ALK融合基因的阳性率。结果胸腔积液中EML4-ALK融合基因的阳性率为12.8%,克唑替尼治疗对于EML4-ALK融合基因的和无EML4-ALK融合基因的患者相比有较高的疾病控制率(80%vs 16.7%,P<0.05)。结论对难以获得组织标本的肺癌患者可选用FQ-PCR法检测肺癌患者恶性胸腔积液中EML4-ALK以指导克唑替尼的应用。

Objective To explore the clinical significance of FQ-PCR to detect EML4-ALK fusion gene in pleural effusion fluid of patients with lung adenocarcinoma. Methods 39 cases of MPE were collected. The mutation of EML4-ALK fusion gene was detected with FQ-PCR. Results There were 5 cases （12. 8%） with EML4-ALK fu-sion gene. Lung adenocarcinoma with EML4-ALK fusion gene had a higher disease control rate than those without mutation （80% vs 16. 7%, P〈0. 05）. Conclusion It is helpful to use FQ-PCR to detect EML4-AL in pleural ef-fusion fluid for patients with lung adenocarcinoma who have lost the opportunity to detect the gene mutation.